11
views
0
recommends
+1 Recommend
3 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Real-time assessment of COVID-19 prevalence among multiple sclerosis patients: a multicenter European study

      brief-report

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          We assessed the prevalence and impact of COVID-19 among multiple sclerosis (MS) patients across Europe by leveraging participant data collected as part of the ongoing EU IMI2 RADAR-CNS major programme aimed at finding new ways of monitoring neurological disorders using wearable devices and smartphone technology. In the present study, 399 patients of RADAR-MS have been included (mean age 43.9 years, 60.7% females) with 87/399 patients (21.8%) reporting major symptoms suggestive of COVID-19. A trend for an increased risk of COVID-19 symptoms under alemtuzumab and cladribine treatments in comparison to injectables was observed. Remote monitoring technologies may support health authorities in monitoring and containing the ongoing pandemic.

          Electronic supplementary material

          The online version of this article (10.1007/s10072-020-04519-x) contains supplementary material, which is available to authorized users.

          Related collections

          Most cited references6

          • Record: found
          • Abstract: found
          • Article: not found

          Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

          Summary Background A recent cluster of pneumonia cases in Wuhan, China, was caused by a novel betacoronavirus, the 2019 novel coronavirus (2019-nCoV). We report the epidemiological, clinical, laboratory, and radiological characteristics and treatment and clinical outcomes of these patients. Methods All patients with suspected 2019-nCoV were admitted to a designated hospital in Wuhan. We prospectively collected and analysed data on patients with laboratory-confirmed 2019-nCoV infection by real-time RT-PCR and next-generation sequencing. Data were obtained with standardised data collection forms shared by WHO and the International Severe Acute Respiratory and Emerging Infection Consortium from electronic medical records. Researchers also directly communicated with patients or their families to ascertain epidemiological and symptom data. Outcomes were also compared between patients who had been admitted to the intensive care unit (ICU) and those who had not. Findings By Jan 2, 2020, 41 admitted hospital patients had been identified as having laboratory-confirmed 2019-nCoV infection. Most of the infected patients were men (30 [73%] of 41); less than half had underlying diseases (13 [32%]), including diabetes (eight [20%]), hypertension (six [15%]), and cardiovascular disease (six [15%]). Median age was 49·0 years (IQR 41·0–58·0). 27 (66%) of 41 patients had been exposed to Huanan seafood market. One family cluster was found. Common symptoms at onset of illness were fever (40 [98%] of 41 patients), cough (31 [76%]), and myalgia or fatigue (18 [44%]); less common symptoms were sputum production (11 [28%] of 39), headache (three [8%] of 38), haemoptysis (two [5%] of 39), and diarrhoea (one [3%] of 38). Dyspnoea developed in 22 (55%) of 40 patients (median time from illness onset to dyspnoea 8·0 days [IQR 5·0–13·0]). 26 (63%) of 41 patients had lymphopenia. All 41 patients had pneumonia with abnormal findings on chest CT. Complications included acute respiratory distress syndrome (12 [29%]), RNAaemia (six [15%]), acute cardiac injury (five [12%]) and secondary infection (four [10%]). 13 (32%) patients were admitted to an ICU and six (15%) died. Compared with non-ICU patients, ICU patients had higher plasma levels of IL2, IL7, IL10, GSCF, IP10, MCP1, MIP1A, and TNFα. Interpretation The 2019-nCoV infection caused clusters of severe respiratory illness similar to severe acute respiratory syndrome coronavirus and was associated with ICU admission and high mortality. Major gaps in our knowledge of the origin, epidemiology, duration of human transmission, and clinical spectrum of disease need fulfilment by future studies. Funding Ministry of Science and Technology, Chinese Academy of Medical Sciences, National Natural Science Foundation of China, and Beijing Municipal Science and Technology Commission.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            A pneumonia outbreak associated with a new coronavirus of probable bat origin

            Since the outbreak of severe acute respiratory syndrome (SARS) 18 years ago, a large number of SARS-related coronaviruses (SARSr-CoVs) have been discovered in their natural reservoir host, bats 1–4 . Previous studies have shown that some bat SARSr-CoVs have the potential to infect humans 5–7 . Here we report the identification and characterization of a new coronavirus (2019-nCoV), which caused an epidemic of acute respiratory syndrome in humans in Wuhan, China. The epidemic, which started on 12 December 2019, had caused 2,794 laboratory-confirmed infections including 80 deaths by 26 January 2020. Full-length genome sequences were obtained from five patients at an early stage of the outbreak. The sequences are almost identical and share 79.6% sequence identity to SARS-CoV. Furthermore, we show that 2019-nCoV is 96% identical at the whole-genome level to a bat coronavirus. Pairwise protein sequence analysis of seven conserved non-structural proteins domains show that this virus belongs to the species of SARSr-CoV. In addition, 2019-nCoV virus isolated from the bronchoalveolar lavage fluid of a critically ill patient could be neutralized by sera from several patients. Notably, we confirmed that 2019-nCoV uses the same cell entry receptor—angiotensin converting enzyme II (ACE2)—as SARS-CoV.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Bias reduction of maximum likelihood estimates

                Bookmark

                Author and article information

                Contributors
                comi.giancarlo@hsr.it
                https://www.radar-cns.org
                Journal
                Neurol Sci
                Neurol. Sci
                Neurological Sciences
                Springer International Publishing (Cham )
                1590-1874
                1590-3478
                2 July 2020
                : 1-4
                Affiliations
                [1 ]GRID grid.18887.3e, ISNI 0000000417581884, Institute of Experimental Neurology, , IRCCS Ospedale San Raffaele, ; via Olgettina 60, 20132 Milan, Italy
                [2 ]GRID grid.18887.3e, ISNI 0000000417581884, Neurorehabilitation Unit, , IRCCS Ospedale San Raffaele, ; Milan, Italy
                [3 ]GRID grid.7080.f, Multiple Sclerosis Centre of Catalonia (Cemcat), Department of Neurology/Neuroimmunology, Hospital Universitari Vall d’Hebron, , Universitat Autònoma de Barcelona, ; Barcelona, Spain
                [4 ]GRID grid.475435.4, Danish Multiple Sclerosis Centre, Department of Neurology, , Copenhagen University Hospital Rigshospitalet, ; Copenhagen, Denmark
                [5 ]GRID grid.13097.3c, ISNI 0000 0001 2322 6764, The Department of Biostatistics and Health informatics, Institute of Psychiatry, Psychology and Neuroscience, , King’s College London, ; London, UK
                [6 ]GRID grid.83440.3b, ISNI 0000000121901201, Institute of Health Informatics, , University College London, ; London, UK
                [7 ]GRID grid.7307.3, ISNI 0000 0001 2108 9006, Embedded Intelligence for Health Care & Wellbeing, , University of Augsburg, ; Augsburg, Germany
                [8 ]GRID grid.497530.c, ISNI 0000 0004 0389 4927, Janssen Research and Development, LLC, ; Titusville, NJ USA
                [9 ]GRID grid.13097.3c, ISNI 0000 0001 2322 6764, The Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, , King’s College London, ; London, UK
                Author information
                http://orcid.org/0000-0002-6989-1054
                Article
                4519
                10.1007/s10072-020-04519-x
                7331489
                32617741
                021185ca-1035-4ff2-bc9f-539c6f540ec9
                © Fondazione Società Italiana di Neurologia 2020

                This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.

                History
                : 3 June 2020
                : 16 June 2020
                Categories
                Covid-19

                Neurosciences
                multiple sclerosis,remote monitoring technologies,covid-19
                Neurosciences
                multiple sclerosis, remote monitoring technologies, covid-19

                Comments

                Comment on this article